Background {#Sec1}
==========

Adverse events (AEs) following intravascular administration of iodinated contrast material (CM) occur in 0.02 to 0.04% of patients. These include kidney injury, respiratory or cardiac arrest, convulsions, and loss of consciousness \[[@CR1]--[@CR3]\]. Renal insufficiency has been noted as both contributing to the risk of a post-CM AEs and as a result thereof \[[@CR4]--[@CR6]\]. However, the incidence of nephropathy specifically caused by iodinated CM is not well understood. As noted by the American College of Radiology, most published studies focus on the diagnosis of post-contrast acute kidney injury (PC-AKI), which is defined as sudden deterioration in renal function within 48 h following the intravascular administration of iodinated CM. PC-AKI is a correlative diagnosis, a subset of PC-AKI cases are contrast-induced nephropathy (CIN or CI-AKI), which is a causative diagnosis \[[@CR7]\]. CI-AKI is commonly defined as an increase in serum creatinine (SCr) greater than 25% or 44.2umol/L (0.5 mg/dL) from baseline within 2 or 3 days of intravascular CM administration in the absence of an alternative cause \[[@CR5], [@CR8]\]. CI-AKI has an estimated incidence of 8 to 20% of cancer patients who undergo contrast-enhanced CT \[[@CR6], [@CR9]--[@CR11]\]. However, most studies do not include a control group for analysis, which is problematic due to the variation in SCr observed in hospitalized patients regardless of CM administration \[[@CR5]\]. Depending on the definition utilized, AKI has been reported in 6 to 35% of inpatients without CM exposure \[[@CR5], [@CR12]\].

Cancer treatments as well as the timing of treatment and CT imaging have been investigated as risk factors for acute reactions to iodinated CM \[[@CR13], [@CR14]\]. Other than chronic kidney disease (CKD), risk factors for CI-AKI include diabetes, hypertension, malignancy, age \> 65 years, use of non-steroidal anti-inflammatory drugs, and timing of CT within 45 days after last chemotherapy \[[@CR9], [@CR15]\]. Regardless of the cause, cancer patients who develop renal failure may have worse prognosis and survival \[[@CR16]--[@CR19]\].

While the biomedical literature indicates that the rate of AEs associated CM use is low, there is little evidence examining the use of CM and the risk of renal AEs in individuals with increasingly common risk factors including cancer and CKD. The objective of this study was to use real world hospital data to test the hypothesis that patients with cancer having CT with iodinated CM would have higher rates of acute renal AEs than those without cancer.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

Data for the study were derived from the Premier Hospital Database, which currently contains data from more than 350 million patient encounters, or one in every five discharges in the United States (US) \[[@CR20]\]. The database contains data from standard hospital discharge files, including a patient's demographic and disease state, and information on billed services, including medications, laboratory, diagnostics and therapeutic services in de-identified patient daily service records. In addition, information on hospital characteristics, including geographic location, bed size and teaching status are also available. Preliminary comparisons between patient and hospital characteristics for the hospitals included in the database and those of the probability sample of hospitals and patients selected for the National Hospital Discharge Survey (NHDS) suggest that the patient populations are similar with regard to patient age, gender, length of stay, mortality, primary discharge diagnosis, and primary procedure groups \[[@CR21]\]. All data used to perform this analysis were de-identified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a de-identified database, the research was exempt from IRB review under 45 CFR 46.101(b)(4).

Inclusion/exclusion criteria {#Sec4}
----------------------------

Any inpatient hospital visit in the Premier Hospital Database from January 1, 2010 through September 30, 2015 was eligible for inclusion. Inpatient was defined as a visit which included an overnight stay. Patient visits were excluded if a patient had a record of end stage renal disease requiring dialysis (ESRD ICD-9 code: 585.6), kidney transplantation (ICD-9 code: V42.0, 996.81, or 55.6×) or AKI (ICD-9 code: 584.9) upon admission (determined by a variable that indicated the patient had the condition upon admission). To isolate the risk of renal events among oncology patients hospitalized for diagnosis or treatment of cancer, visits with a secondary or historical diagnosis of cancer were excluded. Visits where the primary diagnosis or reason for the inpatient stay was cancer were included (Table 5 in [Appendix](#Sec11){ref-type="sec"}).

Variables of interest {#Sec5}
---------------------

Patient visits with a record of primary cancer were further categorized by the following types of cancer: Bone, Breast, Colorectal, Endocrine, Gastrointestinal, Gynecological, Hemolymph, Leukemia, Liver, Lung, Neurological, Respiratory, Skin, Urinary and Miscellaneous (rare cancers).

The primary outcome of interest was a composite of adverse renal events, defined as one or more of the following: AKI, acute renal failure requiring dialysis, CI-AKI or renal failure (ICD-9 codes Table 6 in [Appendix](#Sec11){ref-type="sec"}). Acute renal events were identified as being outcomes if there was a record of the event during the hospitalization and the event of interest was not recorded as present on admission.

To identify usage of CM, keyword text mining was performed on patients' charge master billing files. Using product brand names and generic keywords for CM use, the following categories were created: iodinated, non-iodinated, or unknown type. If no evidence of CM usage was found on the visit, the visit was assumed to have no CM usage. CM usage could have occured during a CT or CTA scan, see Table 7 of [Appendix](#Sec11){ref-type="sec"} for codes used to define CT and CTA scans.

In order to quantify the effect of CKD, a dichotomous variable was made for CKD status based on the presence of CKD stage recorded in the visit. Additionally, an ordinal variable was created for CKD stage (0 = no disease, stage 1, stage 2, stage 3, stages 4 &5) (Table 8 in [Appendix](#Sec11){ref-type="sec"}). It is important to note, that patients with unspecified CKD were only included in the dichotomous variable and excluded in the staging variable due to the non-specificity of their renal disease status.

The following variables were summarized prior to statistical modeling: patient demographics (age, race, gender, insurance type, and admission type), visit characteristics (whether or not the patient underwent a CT, CM usage and type), patient conditions (primary cancer, type of cancer, CKD severity, and overall disease severity as measured by the Elixhauser Comorbidity Index (ECI Table 9 in [Appendix](#Sec11){ref-type="sec"})) \[[@CR22]\]. All components of the composite of renal AEs were described prior to multivariable modeling by the following key model inputs: CKD by severity, CT (with or without iodinated CM) and cancer type.

Statistical analyses {#Sec6}
--------------------

All multivariable renal AE models adjusted for differences in both patient demographics and comorbid conditions. The hospital fixed-effects specification was used to account for time-invariant variation across a hospital that was otherwise unobservable. This methodological choice was made to compensate for the non-random relationship between patients and hospital choice which may result in variation across hospitals in both patient mix (e.g. the share and severity of oncology patients) and in the rate of renal events which may lead to a spurious correlation. By limiting the analysis to variation within hospitals, we study patients treated in a similar environment using similar standards of care and hospital protocols. The decision to utilize a particular product or drug during a hospital visit may depend on formal hospital guidelines, physician practice patterns or preferences, negotiated reimbursement schedules with insurance companies, and other local (geographic and/or hospital) characteristics.

All analysis was performed in SAS version 9.4 (Cary, NC).

Results {#Sec7}
=======

A total of 29,850,475 inpatient visits across 611 hospitals met the study inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). The average age of patients at the time of the inpatient visit was 45 years (standard deviation (sd) 27.5). The majority of patients were female (60%), Caucasian (65%), and the most frequent insurer was Medicare (34%). Emergency and urgent hospitalizations made up 61% of all visits. Overall, 7% of inpatient visits had a record of a CT and 80% of visits had no record of CM (Table [1](#Tab1){ref-type="table"}).Fig. 1Attrition DiagramTable 1Patient Visit CharacteristicsTotalNPercentTotal Visits29,850,475100%Age Median48 Mean45.0 Standard deviation27.50Race Caucasian19,314,45464.7% African-American4,052,60113.6% Other6,483,42021.7%Gender Female17,831,76959.7% Male12,015,26340.3% Unknown34430.0%Insurance Commercial1,681,3085.6% Medicare10,010,10833.5% Medicaid6,968,56923.3% Managed Care8,043,14026.9% Other3,147,35010.5%Admission Type Emergency13,780,88346.2% Urgent4,466,92615.0% Elective7,507,44425.2% Other/Unknown4,095,22213.7%CT Scan2,195,3747.4%Contrast Used Iodinated2,290,1837.7% Non-Iodinated463,9561.6% Both73,8390.2% Unknown3,258,04610.9% None23,764,45179.6%

The population had a mean ECI score of 2.1 (sd 2.17), comorbid conditions and frequencies are shown in Table [2](#Tab2){ref-type="table"}. Among the 6% of visits with CKD, the CKD stage was: stage 1 (0.7%), stage 2 (5.6%), stage 3 (36.5%), stage 4/5 (12.4%) and stage unspecified (44.8%). Cancer was the primary diagnosis in 3.4% of visits. The highest percentage of primary cancer visits reported were: gastrointestinal (16.1%), urinary (14.6%) and lung (13.1%).Table 2Patient ComorbiditiesTotalNPercentTotal Visits29,850,475100%Elixhauser Comorbidities Congestive Heart Failure2,956,9769.9% Cardiac Arrhythmia4,708,60415.8% Valvular Disease1,269,4704.3% Pulmonary Circulation Disorders896,9993.0% Peripheral Vascular Disorders1,392,8474.7% Hypertension (Uncomplicated)10,030,30533.6% Hypertension (Complicated)1,768,1625.9% Paralysis470,5051.6% Other Neurological Disorders2,076,6217.0% Chronic Pulmonary Disease5,651,85918.9% Diabetes (Uncomplicated)4,479,12015.0% Diabetes (Complicated)962,6323.2% Hypothyroidism2,680,9999.0% Renal Failure1,781,5786.0% Liver Disease1,017,9753.4% Peptic Ulcer Disease (excluding bleeding)219,4640.7% AIDS/HIV77,7090.3% Lymphoma50,9770.2% Metastatic Cancer375,8801.3% Solid Tumor without Metastasis816,7232.7% Rheumatoid Arthritis Collagen582,0161.9% Coagulopathy988,2783.3% Obesity3,335,09511.2% Weight Loss985,7993.3% Fluid and Electrolyte Disorders5,086,69517.0% Blood Loss Anemia260,3420.9% Deficiency Anemia711,9872.4% Alcohol Abuse1,672,8625.6% Drug Abuse1,684,0085.6% Psychoses920,0473.1% Depression4,026,00713.5%Elixhauser Comorbidity Index Median2 Mean2.1 Std Dev2.17Chronic Kidney Disease No CKD28,085,08494.0% CKD1,765,3915.9%Stage of Chronic Kidney DiseaseN% Overall% of CKD Stage 111,9580.0%0.7% Stage 299,0040.3%5.6% Stage 3644,3982.2%36.5% Stage 4 & 5219,2550.7%12.4% Unspecified790,7762.6%44.8%Diagnosis of Cancer No Cancer28,828,21997.0% Primary Cancer1,022,2563.4%Type of Primary CancerN% Overall% of Cancer Bone29910.0%0.3% Breast77,4280.3%7.6% Colorectal127,2750.4%12.5% Endocrine37,7690.1%3.7% Gastrointestinal164,3230.6%16.1% Gynecological64,0340.2%6.3% Hemolymph42,5720.1%4.2% Leukemia37,8690.1%3.7% Liver18,0220.1%1.8% Lung133,8370.4%13.1% Miscellaneous120,5560.4%11.8% Neurological29,7240.1%2.9% Respiratory90340.0%0.9% Skin70730.0%0.7% Urinary149,7490.5%14.6%*CKD* Chronic Kidney Disease

The unadjusted rates of the renal AE outcome and its components are reported in Table [3](#Tab3){ref-type="table"} by the following key variables: CKD stage, CT (with or without iodinated CM) and cancer type. The unadjusted baseline rate of the renal AEs was 0.5% for inpatient visits without cancer, CKD or CT and CM. The frequency of renal events increased with CKD severity (0.9% for patients with no record of CKD; 6.1% for a patient with CKD stage 1 to 12.7% among CKD patients stage 4 & 5). Among visits with primary cancer, the unadjusted rate of renal events was 3.0%, an increase from 1.4% in visits with no cancer diagnosis. The unadjusted rate of renal events varied by cancer type: leukemia (5.3%), liver (4.3%), urinary (4.1%), and colorectal (4.1%). When considering all AEs which make up the renal AE composite, AKI without dialysis contributed to the composite more than other components.Table 3Renal Adverse Events: Prior to Multivariable Modeling (Unadjusted)Renal Adverse Event OutcomeComponents of the Renal Adverse Events OutcomeAcute Kidney Injury without dialysisAcute Kidney Injury with dialysisCI-AKIRenal FailureBaseline0.5%0.5%0.0%0.0%0.0%No CKD0.9%0.8%0.0%0.0%0.0%CKD Stage 16.1%6.0%0.1%0.2%0.0%CKD Stage 28.4%8.3%0.1%0.2%0.0%CKD Stage 311.4%11.1%0.3%0.3%0.1%CKD Stage 4&512.7%11.6%0.8%0.3%0.2%CT2.8%2.6%0.1%0.1%0.0%No CT1.3%1.3%0.0%0.0%0.0%CT with Iodinated Contrast2.9%2.8%0.1%0.1%0.0%CT without Iodinated Contrast2.7%2.6%0.1%0.1%0.0%No-Cancer1.4%1.3%0.0%0.0%0.0%Cancer3.0%2.9%0.1%0.0%0.0% Bone1.4%1.3%0.1%0.0%0.0% Breast0.6%0.6%0.0%0.0%0.0% Colorectal4.1%4.0%0.1%0.0%0.0% Endocrine1.5%1.5%0.1%0.0%0.0% Gastrointestinal3.3%3.2%0.1%0.1%0.0% Gynecological2.5%2.4%0.1%0.0%0.0% Hemolymph3.9%3.5%0.3%0.1%0.1% Leukemia5.3%4.9%0.3%0.1%0.1% Liver4.3%4.0%0.2%0.1%0.1% Lung2.8%2.7%0.1%0.1%0.0% Miscellaneous1.9%1.9%0.0%0.0%0.0% Neurological1.0%0.9%0.0%0.0%0.0% Respiratory2.2%2.2%0.0%0.0%0.0% Skin1.6%1.6%0.0%0.0%0.0% Urinary4.1%4.0%0.1%0.0%0.0%*AKI* Acute Kidney Injury, *CKD* Chronic Kidney Disease, *CI-AKI* Contrast induced acute kidney injury

The fixed effects multivariable models controlled for differences in patient demographics and comorbid conditions and decomposed the risk by the following variables: CT, iodinated CM, CKD stage and cancer type (Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). Estimates of absolute risk of the renal AEs are reported with confidence intervals for CT, iodinated CM, CKD stage and cancer (Table [4](#Tab4){ref-type="table"}). Absolute risk of an acute renal event increased with non-contrast CT by 0.2%, iodinated CM increased the risk by an additional 0.8%. The increased risk varied by cancer type, overall, the risk of a renal event increased by 0.9%. The risk by individual cancer types range from 0.3% for endocrine cancer to 2.3% for urinary cancers. Absolute risk increased with CKD severity: stage 1 (2.5%), stage 2 (4.6%), stage 3 (7.2%), stage 4 & 5 (8.1%).Table 4Multivariable Estimates of Absolute risk of an Acute Renal Adverse EventVariableAbsolute Risk Estimate (95% confidence interval)*P*-ValueCT0.19% (0.17, 0.21%)\< 0.0001Iodinated CM0.81% (0.80, 0.83%)\< 0.0001CKD Stage 12.55% (2.35, 2.74%)\< 0.0001CKD Stage 24.64% (4.56, 4.71%)\< 0.0001CKD Stage 37.24% (7.19, 7.28%)\< 0.0001CKD Stage 4/58.14% (8.08, 8.19%)\< 0.0001Cancer0.87% (0.85, 0.89%)\< 0.0001 Urinary2.33% (2.28, 2.39%)\< 0.0001 Leukemia2.20% (2.09, 2.31%)\< 0.0001 Colorectal1.69% (1.63, 1.75%)\< 0.0001 Hemolymph1.22% (1.12, 1.33%)\< 0.0001 Gynecological1.03% (0.95, 1.11%)\< 0.0001 Liver1.00% (0.84, 1.16%)\< 0.0001 Gastrointestinal0.59% (0.54, 0.65%)\< 0.0001 Lung0.33% (0.27, 0.39%)\< 0.0001 Endocrine0.29% (0.18, 0.39%)\< 0.0001*CKD* Chronic Kidney Disease, *CM* Contrast materialFig. 2Renal Event: Multivariable Risk Decomposition -- CT, CM, CKD, and Cancer Type, The percentages shown in Table [4](#Tab4){ref-type="table"}, and in this figure in the columns and at the top of each column differ slightly due to rounding. +CT = record of CT; +Iodinated = record of iodinated contrast material (CM); +CKD = chronic kidney disease, The absolute risk of a renal event can be calculated based on a patient's comorbidities. For example, a patient hospitalized for cancer who had a CT scan with iodinated CM and CKD stage 1, had a 4.9% risk of a renal event. The risk was calculated as follows: (baseline \[.5%\] + CT \[.2%\] with iodinated CM \[.8%\] + CKD stage 1 \[2.5%\] + cancer \[.9%\])

Figure [2](#Fig2){ref-type="fig"} provides a cumulative visual for the regression estimates reported in Table [4](#Tab4){ref-type="table"}. The first bar in the figure is the absolute risk of the renal AEs at baseline, 0.5%. Baseline risk represents patient visits without CT, CM, CKD or cancer. From left to right, the absolute risk associated with each variable is reported as well as how the risk accumulates with each additional variable. For example, a patient hospitalized for cancer that had a CT scan with iodinated CM and CKD stage 1, had a 4.9% risk of a renal event. The absolute risk of a renal event increases substantially for patients with CKD. Inpatients who underwent a CT with iodinated CM who do not have cancer had the following risk based on CKD severity: stage 1 (4.1%), stage 2 (6.2%), stage 3 (8.8%), stage 4 & 5 (9.7%).

Discussion {#Sec8}
==========

After controlling for patient demographics, comorbid conditions and hospital fixed effects, the risk of an acute renal event for hospitalized patients ranges from 0.5% at baseline (patient visits without CT, CM use, CKD or cancer experiencing AKI) to as high as 10.6% (patient visits with a CT with iodinated CM with CKD stage 4 or 5 and cancer). The increasing risk with CKD stage reflects the previously reported impact of compromised renal function and adds to the literature by showing the risk of renal AEs by cancer type. The effect of a cancer diagnosis on the risk of renal AEs was 0.9%, with specific cancers having up to 2.3% (for urinary cancer) added risk. The incremental risk of a renal event associated with a CT without contrast was 0.2%, which clinically may be counterintuitive. This incremental risk was most likely due to the CT being a proxy for sicker patients or other procedures not controlled for in the regression analysis. Regardless of the reason, the effect is small compared to the other factors.

Large retrospective single center studies have previously explored the risk of intravenous CM via propensity-matched cohort analyses \[[@CR23], [@CR24]\]. Such investigations differ from our current analysis in heterogeneity (or homogeneity) of population examined, this study specifically surveyed the inpatient setting while considering the impact of CKD stage and cancer diagnosis.

It is not difficult to surmise why cancer patients may be particularly susceptible to renal events given their high prevalence of renal insufficiency, concomitant nephrotoxic chemotherapeutic regimens, and predisposition to dehydration secondary to advanced age, poor appetite, nausea, and vomiting \[[@CR25]\]. It has additionally been suggested that patients with active cancer undergoing CM enhanced CT are particularly at risk of CI-AKI even in the absence of significant renal impairment as underlying renal insufficiency may be masked due to falsely low creatinine concentration resulting from diminished muscle mass \[[@CR10]\].

This study did not explore the potential additive effects of different types of CM and chemotherapy; however, it has been suggested that CI-AKI may develop 4.5 times more frequently in cancer patients who undergo recent chemotherapy \[[@CR9]\] and that exposure to CM within a week prior to nephrotoxic chemotherapeutic agents, for example cisplatin, significantly increases the risk of nephropathy \[[@CR26]\]. Similar nephrotoxic effects of iodinated CM and chemotherapeutic agents upon the renal vasculature may rationalize the amplified risk. Not surprisingly, chemotherapy has been increasingly identified as an additional risk factor, evident by inclusion into CI-AKI consensus statements and guideline recommendations \[[@CR27]\].

While the current analysis did not assess renal AEs by class of CM, a recent prospective, multicenter, randomized controlled trial suggested more favorable safety profile of iso-osmolar CM (iodixanol) versus low-osmolar CM (iopromide) in low risk cancer patients defined by eGFR\> 60 mL/min \[[@CR28]\]. Adequately sized and designed studies of prospective nature are warranted to elucidate findings further.

Our findings quantify absolute risk of renal events and are noteworthy given the marked consequences that AKI may elicit within the oncology setting. Salahudeen et al. recently conducted cross-sectional analysis of prospectively collected data on 3558 patients admitted to the University of Texas, M.D. Anderson Cancer Center and found higher rates of AKI versus most non-cancer settings. In patients with AKI, length of stay (100%), cost (106%), and odds for mortality (4.7-fold) were significantly greater \[[@CR29]\].

On account of these implications and due to the complex bidirectional relationship between cancer and kidney function, there is need for further investigation and periprocedural recommendations. The intra-arterial administration of CM within interventional cardiovascular procedures has been investigated at length, with subsequent guideline development central to patient risk assessment, hydration strategies, and emphasis on limiting volumes of CM administered. While it has been suggested that overall risk is lower with intravenous administration of CM, susceptible oncologic settings and vulnerable patients should be identified (particularly a patient's state of kidney health and timing of treatment or imaging) and integrated strategies should be employed to minimize the risk of renal events among inpatient cancer patients undergoing CT with CM.

The intricate association and increasing prevalence of cancer and AKI/CKD has led to mounting interest in this complex environment and prompted evolution of the novel onco-nephrology subspecialty. Yet the relationship between cancer therapy and kidney disease remains underexplored. The burgeoning area of onco-nephrology suffers from lack of guidance for clinicians who encounter difficult and often complex problems in this complicated group of patients, and development of integrated guidelines is needed \[[@CR30]\]. The 2016 American Society of Nephrology (ASN) Onco-Nephrology Curriculum may strengthen and expand understanding of this field by underscoring risk factors of CI-AKI and suggesting preventive measures be taken in patients with GFR \< 60 mL/min including limiting contrast volume, using iso-osmolar contrast, prehydration with normal saline, and discontinuation of concurrent nephrotoxic agents \[[@CR31]\].

To our understanding, this is the first study to quantify absolute risk of renal events in a robust multicenter cohort of patients undergoing CM enhanced CT with decomposed analysis of contributing factors to include CM, renal function, and cancer diagnosis. Our analysis suggests that patients who receive CM are at higher risk versus those who do not. Additionally, risk is heightened with progressively advanced stages of CKD. Further, our results substantiate multiple prior reports that cancer patients may be more uniquely susceptible to renal events undergoing CM enhanced CT versus non-cancer patients. Vulnerability of the oncologic cohort is likely multifactorial in nature and due, in part, to a high prevalence of renal insufficiency, dehydration, cachectic condition, and serial/additive renal insults induced by multiple exposures to CM, nephrotoxic medications and chemotherapeutic regimens. Results derived from our analysis may enable significant comparison of future analyses across procedures and selected high-risk populations, ultimately driving investigative research efforts and steering quality improvement endeavors.

Strengths and limitations {#Sec9}
-------------------------

Strengths of this study include the use of a comprehensive data source and use of the hospital fixed-effect specification methodology that allowed for control of time-invariant within hospital variation that is otherwise unobservable, such as physician preferences and internal protocols. The limitations of this study are those that are inherent in retrospective database analyses, which include the unit of inference (which is the visit not the patient) and potential under coding of non-billable events. The data source for this study was the Premier Healthcare Database that represents 20% of all inpatient discharges in the US; however, given its reliance on ICD-9 Codes, there is a potential risk of coding errors. A second limitation of this data source is that it does not track patients longitudinally. Thus, it was not possible to determine if events occurred after the patient was discharged. Due to the administrative nature of the database, laboratory values (sCr and GFR) were not available, we could not define CI-AKI by sCr, and rather, the outcome was defined by the ICD-9 code for CI-AKI which may underestimate the occurrence of this event. Finally, due to limitations of the dataset, we were unable to ascertain total volumes of CM administered, use of hydration strategies, or concomitant use of nephrotoxic medications or chemotherapeutic regimens.

Conclusions {#Sec10}
===========

This large retrospective multicenter study decomposed the risk of acute renal events among hospitalized cancer patients having CT either with or without iodinated CM. The baseline risk for an acute renal event in patients without cancer or CKD and no CT or CM was 0.5%. When a CT procedure was performed with iodinated CM the risk increased to 1.5%. Patients with CKD having a CT with CM had an increased risk of an acute renal event from 2.5 to 8.1% depending on the stage of CKD. Among cancer patients, the overall risk increased from baseline by 0.9%. Risk increase from baseline by type of cancer ranged from 0.3 for endocrine and lung cancer to over 2% for leukemia and urinary cancer. Therefore, cancer patients having CT with iodinated CM without CKD have a risk increase of 2.4% and when CKD is present the risk ranges from 4.9 to 10.5% depending on CKD stage. In the changing healthcare landscape, with complex inpatient admissions, understanding the underlying risks of acute renal events will be an important consideration in treatment choices for oncology patients.

Appendix {#Sec11}
========

Table 5Cancer CodingICD-9 Diagnosis Code 3 Digit GroupICD-9 Diagnosis Code Group DescriptionCancer Category140MALIGNANT NEOPLASM LIPGastrointestinal141MALIG NEO TONGUEGastrointestinal142MAL NEO MAJOR SALIVARYGastrointestinal143MALIGNANT NEOPLASM GUMGastrointestinal144MALIG NEO MOUTH FLOORGastrointestinal145MALIG NEO MOUTH NEC/NOSGastrointestinal146MALIG NEO OROPHARYNXGastrointestinal147MALIG NEO NASOPHARYNXRespiratory148MALIG NEOPL HYPOPHARYNXRespiratory149OTH MALIG NEO OROPHARYNXGastrointestinal150MALIGNANT NEO ESOPHAGUSGastrointestinal151MALIGNANT NEO STOMACHGastrointestinal152MALIG NEO SMALL BOWELGastrointestinal153MALIGNANT NEOPLASM COLONColorectal154MALIG NEO RECTUM/ANUSColorectal155MALIGNANT NEOPLASM LIVERLiver156MAL NEO GB/EXTRAHEPATICGastrointestinal157MALIGNANT NEO PANCREASGastrointestinal158MALIG NEO PERITONEUMGastrointestinal159OTH MALIG NEO GI/PERITONGastrointestinal160MAL NEO NASAL CAV/SINUSRespiratory161MALIGNANT NEO LARYNXRespiratory162MAL NEO TRACHEA/LUNGLung163MALIGNANT NEOPL PLEURALung164MAL NEO THYMUS/MEDIASTINLung165OTH/ILL-DEF MAL NEO RESPMiscellaneous170MAL NEO BONE/ARTIC CARTBone171MAL NEO SOFT TISSUEMiscellaneous172MALIGNANT MELANOMA SKINSkin173OTHER MALIG NEOPL SKINSkin174MALIG NEO FEMALE BREASTBreast175MALIG NEO MALE BREASTBreast176KAPOSI'S SARCOMAMiscellaneous179NEOPLASM, MALIGNANT, UTERUS NECGynecological180MALIG NEOPL CERVIX UTERIGynecological181NEOPLASM, MALIGNANT, PLACENTAGynecological182MALIG NEOPL UTERUS BODYGynecological183MAL NEO UTERINE ADNEXAGynecological184MAL NEO FEM GEN NEC/NOSGynecological185NEOPLASM, MALIGNANT, PROSTATEUrinary186MALIGN NEOPL TESTISUrinary187MAL NEO MALE GENITAL NECUrinary188MALIGN NEOPL BLADDERUrinary189MAL NEO URINARY NEC/NOSUrinary190MALIGNANT NEOPLASM EYENeurological191MALIGNANT NEOPLASM BRAINNeurological192MAL NEO NERVE NEC/NOSNeurological193NEOPLASM, MALIGNANT, THYROID GLANDEndocrine194MAL NEO OTHER ENDOCRINEEndocrine195MAL NEO OTH/ILL-DEF SITEMiscellaneous196MALIG NEO LYMPH NODESHemolymph197SECONDRY MAL NEO GI/RESPGastrointestinal198SEC MALIG NEO OTH SITESMiscellaneous199MALIGNANT NEOPLASM NOSMiscellaneous200LYMPHOSARC/RETICULOSARCHemolymph201HODGKIN'S DISEASEHemolymph202OTH MAL NEO LYMPH/HISTIOHemolymph203MULTIPLE MYELOMA ET ALLeukemia204LYMPHOID LEUKEMIALeukemia205MYELOID LEUKEMIALeukemia206MONOCYTIC LEUKEMIALeukemia207OTHER SPECIFIED LEUKEMIALeukemia208LEUKEMIA-UNSPECIF CELLLeukemia209.0×-209.3×NEUROENDOCRINE TUMORSEndocrine230CA IN SITU DIGESTIVE ORGGastrointestinal231CA IN SITU RESPIRATORYRespiratory232CARCINOMA IN SITU SKINSkin233CA IN SITU BREAST/GUBreast234CA IN SITU NEC/NOSMiscellaneous235UNC BEHAV NEO GI/RESPGastrointestinal236UNC BEHAV NEO GUUrinary237UNCER NEO ENDOCRINE/NERVEndocrine238UNC BEHAV NEO NEC/NOSMiscellaneous239UNSPECIFIED NEOPLASMMiscellaneous

Table 6Safety EventsAdverse Event CategoryICD-9 Diagnosis Code(s)Acute Kidney Injury584.9 Contrast-induced nephropathy (CIAKI)584.9 + E947.8 Acute Kidney Injury requiring dialysis584.9 + 39.95Renal Failure586.x

Table 7Radiologic ImagingCodeDescriptionSub-CategoryCategoryICD-987.03C.A.T. SCAN OF HEADCT - DiagnosticCT87.41C.A.T. SCAN OF THORAXCT - DiagnosticCT87.71C.A.T. SCAN OF KIDNEYCT - DiagnosticCT88.01C.A.T. SCAN OF ABDOMENCT - DiagnosticCT88.38OTHER C.A.T. SCANCT - DiagnosticCTCPT70,450CT HEAD/BRAIN W/O DYECT - DiagnosticCT70,460CT HEAD/BRAIN W/DYECT - DiagnosticCT70,470CT HEAD/BRAIN W/O & W/DYECT - DiagnosticCT70,480CT ORBIT/EAR/FOSSA W/O DYECT - DiagnosticCT70,481CT ORBIT/EAR/FOSSA W/DYECT - DiagnosticCT70,482CT ORBIT/EAR/FOSSA W/O&W/DYECT - DiagnosticCT70,486CT MAXILLOFACIAL W/O DYECT - DiagnosticCT70,487CT MAXILLOFACIAL W/DYECT - DiagnosticCT70,488CT MAXILLOFACIAL W/O & W/DYECT - DiagnosticCT70,490CT SOFT TISSUE NECK W/O DYECT - DiagnosticCT70,491CT SOFT TISSUE NECK W/DYECT - DiagnosticCT70,492CT SFT TSUE NCK W/O & W/DYECT - DiagnosticCT70,496CT ANGIOGRAPHY HEADCT Angiography - DiagnosticCTA70,498CT ANGIOGRAPHY NECKCT Angiography - DiagnosticCTA71,250CT THORAX W/O DYECT - DiagnosticCT71,260CT THORAX W/DYECT - DiagnosticCT71,270CT THORAX W/O & W/DYECT - DiagnosticCT71,275CT ANGIOGRAPHY CHESTCT Angiography - DiagnosticCTA72,125CT NECK SPINE W/O DYECT - DiagnosticCT72,126CT NECK SPINE W/DYECT - DiagnosticCT72,127CT NECK SPINE W/O & W/DYECT - DiagnosticCT72,128CT CHEST SPINE W/O DYECT - DiagnosticCT72,129CT CHEST SPINE W/DYECT - DiagnosticCT72,130CT CHEST SPINE W/O & W/DYECT - DiagnosticCT72,131CT LUMBAR SPINE W/O DYECT - DiagnosticCT72,132CT LUMBAR SPINE W/DYECT - DiagnosticCT72,133CT LUMBAR SPINE W/O & W/DYECT - DiagnosticCT72,191CT ANGIOGRAPH PELV W/O&W/DYECT Angiography - DiagnosticCTA72,192CT PELVIS W/O DYECT - DiagnosticCT72,193CT PELVIS W/DYECT - DiagnosticCT72,194CT PELVIS W/O & W/DYECT - DiagnosticCT73,200CT UPPER EXTREMITY W/O DYECT - DiagnosticCT73,201CT UPPER EXTREMITY W/DYECT - DiagnosticCT73,202CT UPPR EXTREMITY W/O&W/DYECT - DiagnosticCT73,206CT ANGIO UPR EXTRM W/O&W/DYECT Angiography - DiagnosticCTA73,700CT LOWER EXTREMITY W/O DYECT - DiagnosticCT73,701CT LOWER EXTREMITY W/DYECT - DiagnosticCT73,702CT LWR EXTREMITY W/O&W/DYECT - DiagnosticCT73,706CT ANGIO LWR EXTR W/O&W/DYECT Angiography - DiagnosticCTA74,150CT ABDOMEN W/O DYECT - DiagnosticCT74,160CT ABDOMEN W/DYECT - DiagnosticCT74,170CT ABDOMEN W/O & W/DYECT - DiagnosticCT74,175CT ANGIO ABDOM W/O & W/DYECT Angiography - DiagnosticCTA74,261CT COLONOGRAPHY DXCT - DiagnosticCT74,262CT COLONOGRAPHY DX W/DYECT - DiagnosticCT74,263CT COLONOGRAPHY SCREENINGCT - DiagnosticCT75,571CT HRT W/O DYE W/CA TESTCT - DiagnosticCT75,572CT HRT W/3D IMAGECT - DiagnosticCT75,573CT HRT W/3D IMAGE CONGENCT - DiagnosticCT75,574CT ANGIO HRT W/3D IMAGECT Angiography - DiagnosticCTA75,635CT ANGIO ABDOMINAL ARTERIESCT Angiography - DiagnosticCTA76,380CAT SCAN FOLLOW-UP STUDYCT - DiagnosticCT76,497CT PROCEDURECT - DiagnosticCT77,011CT SCAN FOR LOCALIZATIONCT - GuidanceCT77,012CT SCAN FOR NEEDLE BIOPSYCT - GuidanceCT77,013CT GUIDE FOR TISSUE ABLATIONCT - GuidanceCT77,014CT SCAN FOR THERAPY GUIDECT - GuidanceCT77,078CT BONE DENSITY AXIALCT - DiagnosticCT77,079CT BONE DENSITY, PERIPHERALCT - DiagnosticCT0042 TCT PERFUSION W/CONTRAST, CBFCT - DiagnosticCT & CTAS8092ELECTRON BEAM COMPUTED TOMOGCT - DiagnosticCT

Table 8Chronic Kidney DiseaseChronic Kidney Disease StageICD-9 Diagnosis Code(s)Chronic Kidney Disease Stage 1585.1Chronic Kidney Disease Stage 2585.2Chronic Kidney Disease Stage 3585.3Chronic Kidney Disease Stage 4585.4Chronic Kidney Disease Stage 5585.5Chronic Kidney Disease, unspecified585.9

Table 9Elixhauser Comorbidity Index\*ComorbidityCodesCongestive Heart Failure398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4--425.9, 428.xCardiac Arrhythmia426.0, 426.13, 426.7, 426.9, 426.10, 426.12, 427.0--427.4, 427.6--427.9, 785.0, 996.01, 996.04, V45.0, V53.3Valvular Disease093.2, 394.x--397.x, 424.x, 746.3--746.6, V42.2, V43.3Pulmonary Circulation Disorders415.0, 415.1, 416.x, 417.0, 417.8, 417.9Peripheral Vascular Disorders093.0, 437.3, 440.x, 441.x, 093.0, 437.3, 440.x, 441.x, 443.1--443.9, 447.1, 557.1, 557.9, V43.4Hypertension (Uncomplicated)401.xHypertension (Complicated)402.x--405.xParalysis334.1, 342.x, 343.x, 344.0--344.6, 344.9Other Neurological Disorders331.9, 332.0, 332.1, 333.4, 333.5, 333.92, 334.x--335.x, 336.2, 340.x, 341.x, 345.x, 348.1, 348.3, 780.3, 784.3Chronic Pulmonary Disease416.8, 416.9, 490.x − 505.x, 506.4, 508.1, 508.8Diabetes (Uncomplicated)250.0--250.3Diabetes (Complicated)250.4--250.9Hypothyroidism240.9, 243.x, 244.x, 246.1, 246.8Renal Failure403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.x, 586.x, except 585.6, 588.0, V42.0, V45.1, V56.xEnd-stage renal disease585.6Liver Disease070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 456.0--456.2, 570.x, 571.x, 572.2--572.8, 573.3, 573.4, 573.8, 573.9, V42.7Peptic Ulcer Disease (excluding bleeding)531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9AIDS/HIV042.x--044.xLymphoma200.x--202.x, 203.0, 238.6Metastatic Cancer196.x--199.xSolid Tumor without Metastasis140.x--172.x, 174.x--195.xRheumatoid Arthritis Collagen446.x, 701.0, 710.0--710.4, 710.8, 710.9, 711.2, 714.x, 719.3, 720.x, 725.x, 728.5, 728.89, 729.30Coagulopathy286.x, 287.1, 287.3--287.5Obesity278.0Weight Loss260.x--263.x, 783.2, 799.4Fluid and Electrolyte Disorders253.6, 276.xBlood Loss Anemia280.0Deficiency Anemia280.1--280.9, 281.xAlcohol Abuse265.2, 291.1--291.3, 291.5--291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0--571.3, 980.x, V11.3Drug Abuse292.x, 304.x, 305.2--305.9, V65.42Psychoses293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.xDepression296.2, 296.3, 296.5, 300.4, 309.x, 311\*The ECI Score includes 31 categories (Table [9](#Tab9){ref-type="table"} in [Appendix](#Sec11){ref-type="sec"}) of comorbidities, which are associated with mortality. Each category counts as 1 point for a potential ECI score range of 0--31. These comorbidities were identified using diagnosis codes that appear during the visit

AE

:   Adverse event(s)

AKI

:   Acute kidney injury

ASN

:   American Society of Nephrology

CI-AKI

:   Contrast-induced acute kidney injury

CIN

:   Contrast-induced nephropathy

CKD

:   Chronic kidney disease

CM

:   Contrast material

CT

:   Computed tomography

ECI

:   Elixhauser comorbidity index

ESRD

:   End stage renal disease

ICD-9

:   International classification of diseases, ninth revision

NHDS

:   National Hospital Discharge Survey

PC-AKI

:   Post-contrast acute kidney injury

SCr

:   Serum creatinine

US

:   United States
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